Research LetterBeta-blocker and ACE-inhibitor dosing as a function of body surface area: From the HF-ACTION trial
Section snippets
Disclosures
Dr. Greene has received a Heart Failure Society of America/ Emergency Medicine Foundation Acute Heart Failure Young Investigator Award funded by Novartis; receives research support from the American Heart Association, Amgen, AstraZeneca, Bristol-Myers Squibb, Merck, Novartis; has served on advisory boards for Amgen and Cytokinetics; and serves as a consultant for Amgen and Merck. Dr. Mentz receives research support and honoraria from Abbott, American Regent, Amgen, AstraZeneca, Bayer,
REFERENCES (8)
- et al.
Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction
J Am Coll Cardiol
(2019) - et al.
Heart failure and a controlled trial investigating outcomes of exercise training (HF-ACTION): design and rationale
Am Heart J
(2007) - et al.
2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the american college of cardiology task force on expert consensus decision pathways
J Am Coll Cardiol
(2018) - et al.
Body surface area and medication dosing in patients with heart failure with reduced ejection fraction
Trends Cardiovasc Med
(2020)
There are more references available in the full text version of this article.
Cited by (1)
Advances in Targeting ACE2 for Developing COVID-19 Therapeutics
2022, Annals of Biomedical Engineering
Funding Sources: None.
© 2020 Elsevier Inc. All rights reserved.